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bstract
Dissolution research started to develop about 100 years ago as a field of physical chemistry and since then important progress has been made.
owever, explicit interest in drug related dissolution has grown only since the realisation that dissolution is an important factor of drug bioavailability
n the 1950s. This review attempts to account the most important developments in the field, from a historical point of view. It is structured in
chronological order, from the theoretical foundations of dissolution, developed in the first half of the 20th century, and the development of a
elationship between dissolution and bioavailability in the 1950s, going to the more recent developments in the framework of the Biopharmaceutics
lassification System (BCS). Research on relevant fields of pharmaceutical technology, like sustained release formulations, where drug dissolution
lays an important role, is reviewed. The review concludes with the modern trends on drug dissolution research and their regulatory implications.
2006 Elsevier B.V. All rights reserved.
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1. Introduction
Oral administration of solid formulations has been the major
route of drug administration for almost a century. However, it∗ Corresponding author. Tel.: +30 2107274026; fax: +30 2107274027.
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was only 50 or so years ago that scientists realised the impor-
tance of dissolution processes in the physiological availability
of drugs. In the meanwhile, the study of the dissolution process
has been developing since the end of the 19th century by phys-
ical chemists. Therefore, most of the fundamental research in
the field was not related to drugs at all, and the basic laws for
the description of the dissolution process were already available
when interest in drug dissolution started to rise.
2 nal Journal of Pharmaceutics 321 (2006) 1–11
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Fig. 2. Concentration–time plots of (Noyes and Whitney, 1897) data together
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This review attempts to describe the historical evolution of
rug dissolution. It places particular emphasis on the fundamen-
al articles in the field, which shaped the major lines of research
nd regulation policy of the regulatory agencies. Also, paral-
el research contributions with significant impact on dissolution
esearch are quoted. The present review is structured in chrono-
ogical order, starting from the first dissolution experiment and
he development of the major models for dissolution of solids,
oving on to the realization of a relationship between dissolu-
ion and bioavailability, which initiated the drug related interest
n dissolution, and progressing to the present applications of dis-
olution studies, with both their scientific and regulatory aspects.
. 1897–1960: The foundations of dissolution research
In 1897, Noyes and Whitney conducted the first dissolu-
ion experiments and published an article entitled “the rate of
olution of solid substances in their own solutions” (Noyes and
hitney, 1897). Arthur A. Noyes [1866–1936], was a Profes-
or of Chemistry at MIT and also served as a president of MIT
rom 1907 to 1909, later moving to Caltech. Together with Willis
. Whitney, they studied the dissolution of two sparingly solu-
le compounds, benzoic acid and lead chloride. The materials
ere laid around glass cylinders which were submerged into
essels containing water. The cylinders were rotated at constant
peed and under constant temperature. The authors noticed that
he rate of dissolution is proportional to the difference between
he instantaneous concentration, C at time t, and the saturation
olubility, CS, (Fig. 1). This statement can be formulated math-
matically as follows:
dC
dt
= k(CS − C) (1)
ig. 1. Three extracts from the original article of Noyes and Whitney (1897)
howing the title, the main equation and the concluding statement of the article.
eprinted with permission.
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he data correspond to stick no. 1 for benzoic acid and stick no. 2 for lead
hloride.
here k is a constant. The experiment configuration ensured that
he surface of the materials was kept constant during dissolution
s the materials were in excess of the amount needed to saturate
he medium. In Fig. 2 plots of these data together with plots of Eq.
1) using the original estimates for the values of the constants, are
hown. The authors attributed the mechanism of dissolution to
thin diffusion layer which is formed around the solid surface
nd through which the molecules diffuse to the bulk aqueous
hase.
The next development came from Erich Brunner, and Stanis-
aus von Tolloczko at Gottingen, who published an article in
900 based on a series of experiments that extended the condi-
ions under which Eq. (1) holds and also showed that the rate of
issolution depends on the exposed surface, the rate of stirring,
emperature, structure of the surface and the arrangement of the
pparatus (Bruner and Tolloczko, 1900). The proposed model
as derived from Eq. (1) by letting k = k1S:
dC
dt
= k1S(CS − C) (2)
here S is the surface area. Also, Brunner in 1904 published a
aper based on the work done in his Ph.D. that studied the prob-
em further, trying to find specific relations between the constants
nvolved (Brunner, 1904). This work was published together
ith the theoretical work of Walther Nernst [1864–1941], who
as Professor of Physical Chemistry and the founder and direc-
or of the Institute for Physical Chemistry and Electrochem-
stry at Gottingen where Brunner was working (Nernst, 1904).
alther Nernst was one of the major contributors in the field
f physical chemistry, and received a Nobel Prize in 1920 “in
ecognition of his work in thermochemistry”. The main result of
his two-part publication of Nernst and Brunner in 1904, which
as based on the diffusion layer concept and Fick’s second law
as what is known as the Nernst–Brunner equation, which was
erived from Eq. (2) by letting k1 = D/(Vh):
dC
dt
= DS
Vh
(CS − C) (3)
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here D is the diffusion coefficient, h the thickness of the dif-
usion layer and V is the volume of the dissolution medium.
In 1931 Hixson and Crowell expressed the surface, S of Eq.
2) in respect to the weight, w, by letting S to be proportional to
2/3
, which makes the Eq. (2) applicable to dissolving compact
bjects (Hixson and Crowell, 1931). By this consideration, Eq.
2), when integrated yields an equation which relates time to the
ubic-root of weight and in the special case of sink conditions,
here small concentrations are considered and the difference
Cs −C) can be considered as constant, the cubic-root law takes
simple form:
1/3
0 − w1/3 = k2t (4)
here w0 is the initial weight and k2 a constant. In their paper
ixson and Crowell reported that the Noyes–Whitney equation
n its original form and without any details about the mechanism
f the process had been sufficiently validated with a wide range
f experiments, as opposed to the various mechanistic explana-
ions that had appeared, none of which was entirely satisfactory.
The above approaches can be categorized as various expres-
ions of the diffusion layer model as a physical explanation for
issolution process, where the limiting step has been consid-
red to be the diffusion of molecules through a stagnant film of
iquid around the solid surface. By the 1950s two more alterna-
ive explanations were available as reviewed by Higuchi (1961).
he interfacial barrier model, considered that interfacial trans-
ort, rather than diffusion through the film, is the limiting step
ue to a high activation energy level for the former. This model
as first proposed by Wilderman (1909) and was also consid-
red by Zdanovskii (1946), but has not been studied in detail and
n explicit mathematical description for the dissolution kinetics
s not available, while variations have also appeared (Miyamoto,
933). The third model for dissolution is Danckwerts’ model,
hich appeared in 1951 (Danckwerts, 1951). According to this,
onstantly renewed macroscopic packets of solvent reach the
olid surface and absorb molecules of solute, delivering them to
he solution. Combinations of these models were also consid-
red. The work of Levich improved the theoretical model of the
issolution experiment using rotating disks, taking into account
he centrifugal force on diffusion (Levich, 1962).
Despite the advances in in vitro dissolution in chemical engi-
eering sciences, in the pharmaceutical sciences the concept was
ot used extensively until the early 1950s. Until then the in vivo
vailability of the drug was thought to be determined solely by
he disintegration of the tablet, ignoring the dissolution process.
any in vitro procedures to determine the disintegration time
f tablets were suggested, at the time, and some of them were
eviewed by Morrison and Campbell (1965). The first official
isintegration test for tablets was published in the Pharmacopeia
elvetica in 1934, which used water at 37 ◦C as the medium and
eriodical shaking, while in the United States Pharmacopeia the
isintegration test was introduced in the 14th edition in 1950.
ther methods, developed later, tried to introduce more realistic
onditions, using, for example, simulated gastric fluids as media
or the disintegration experiments. One of the most sophisti-
ated was Filleborn’s method which was published in 1948 and
t
i
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ntroduced an artificial stomach with simulated in vivo condi-
ions, including pH level, peristalsis and the presence of food
Filleborn, 1948). In the early 1950s it became clear that disinte-
ration alone could not account for the physiological availability
f drugs and in many cases the dissolution rate was, instead, the
imiting step.
. 1950–1980: The development of a relationship
etween dissolution and bioavailability
To the best of authors’ knowledge, Edwards in 1951 was the
rst to appreciate that following the oral administration of solid
osage forms, if the absorption process of drug from the gastroin-
estinal tract is rapid, then the rate of dissolution of that drug can
e the step which controls its appearance in the body. In fact, he
ostulated that the dissolution of an aspirin tablet in the stomach
nd intestine would be the rate process controlling the absorp-
ion of aspirin into the blood stream (Edwards, 1951). However,
elson in 1957 was the first to explicitly relate the blood levels
f orally administered theophylline salts to their in vitro disso-
ution rates (Nelson, 1957). He used a non-disintegrating drug
ellet, (mounted on a glass side so that only the upper face was
xposed), placed at the bottom of a 600 mL beaker in such a
anner that it could not rotate when the dissolution medium
as stirred at 500 rpm.
In mid 1960s to early 1970s a number of studies demonstrat-
ng the effect of dissolution on the bioavailability of a variety
f drugs were reported in the literature. Two reports were pub-
ished in 1963 and 1964 drawing attention to the lack of full
linical effect for two brands of tolbutamide marketed in Canada
Campagna et al., 1963; Levy et al., 1964). These tablets were
hown to have long disintegration times as well as slow dis-
olution characteristics (Levy, 1964). Besides, a slight change
n formulation of an experimental tolbutamide preparation was
hown to produce significantly lower blood levels and hypo-
lycemic effect (Varley, 1968). In 1968, Martin et al. (1968)
eported significant differences in the bioavailability between
ifferent brands of sodium diphenylhydantoin, chlorampheni-
ol and sulfisoxazole. MacLeod et al. (1972) reported greater
han 20% difference in peak concentration and area under the
erum concentration–time curve for three ampicillin products.
In late sixties it was realized that differences in product
ormulation could lead to large differences in speed of onset,
ntensity and duration of drug response. At that time the term
bioavailability” was coined to describe either the extent to
hich a particular drug is utilized pharmacologically or, more
trictly, the fraction of dose reaching the general circulation. The
ost dramatic bioavailability examples have been with digoxin
n the U.K. and the USA in 1971 and phenytoin in Australia and
ew Zealand in 1968.
In the former case, different formulations of digoxin yielded
p to sevenfold differences in serum digoxin levels (Lindenbaum
t al., 1971). These observations prompted the FDA in collabora-
ion with the late John Wagner to carry detailed dissolution stud-
es on 44 lots from 32 manufacturers of 0.25 mg digoxin tablets
vailable in the 1972 North American market-place (Skelly,
988). The studies revealed tremendous differences in the dis-
4 A. Dokoumetzidis, P. Macheras / International Journal of Pharmaceutics 321 (2006) 1–11
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extended-release products in 1995.
It should also be noted that the first guidelines for dissolution
testing of solid dosage forms were published in 1981 as a joint
report of the Section for Official Laboratories and Medicines
Table 1
Number of monographs in the US Pharmacopeia and the National Formulary
which require dissolution or release tests
Edition/year Monographs for
immediate-release
dosage forms
Monographs for
modified-release
dosage forms
Extended Delayed
USP 18-NF 13/1970 6 – –
USP 19-NF 14/1975 12 – –
USP 20-NF 15/1980 60 – –
USP 21-NF 16/1985 400 1 –ig. 3. Dissolution profiles of three different formulations of digoxin, exhibiting
arge differences, reprinted from (Fraser et al., 1972) with permission.
olution profiles of the digoxin products and substantiated the
iew that either lot-to-lot or amongst brands bioinequivalence
riginates from differences in dissolution rates. Additional dis-
olution studies conducted in other laboratories confirmed these
ndings (Fraser et al., 1972). In Fig. 3 dissolution profiles of
ifferent formulations of digoxin are shown from (Fraser et al.,
972) exhibiting large differences.
Phenytoin toxicity occurred in a large number of patients
hen the manufacturer replaced the excipient calcium sulfate
ith lactose in immediate release phenytoin tablets (Tyrer et al.,
970). Initially, the lower extent of absorption of phenytoin in
he presence of calcium sulfate was ascribed to the formation of
n insoluble calcium-phenytoin salt, Bochner et al. (1972). How-
ver, Chapron et al. (1979) found no effect when they studied
he influence of calcium on bioavailability of phenytoin admin-
stering calcium gluconate before, with and after a single dose
f 300 mg of phenytoin. These results indicated that the higher
ydrophilicity of lactose compared to calcium sulfate, promoted
he dissolution rate of phenytoin resulting in higher bioavail-
bility and consequently higher concentrations of phenytoin in
lasma, exceeding its narrow therapeutic range of 10–20g/mL.
he results of this study are shown in Fig. 4. A decade later,
oss of seizure control occurred in a patient on phenytoin was
elated to altered dissolution characteristics caused by the phys-
cal changes of phenytoin capsules (Cloyd et al., 1980).
.1. 1970: Initiation of the ofﬁcial dissolution tests
All of the above bioavailability concerns prompted the intro-
uction of dissolution requirements in tablet and capsule mono-
raphs in pharmacopeias. Of equal significance was the recog-
ition of the immense value of dissolution testing as a tool for
uality control. Thus, equivalence in dissolution behaviour was
ought in light of both the bioavailability and quality control
onsiderations throughout the last 35 years.
As mentioned above a number of studies mainly in the USA
uring the 20-year period 1950–1970 shed light on the impor-
ance of pharmaceutical ingredients and processes in regard to
he dissolution–bioavailability relationship. As a result of these
evelopments, the basket-stirred-flask test (USP apparatus 1)
U
U
U
Uig. 4. Plot of blood phenytoin concentrations, reprinted with permission from
Tyrer et al., 1970), including the original legend.
as adopted as an official dissolution test in 6 monographs of
he United States Pharmacopeia (USP) and National Formulary
NF) in 1970. Due to the continuous intense interest in the sub-
ects of dissolution and gastrointestinal absorption, an explosion
n the number of monographs of the dissolution requirements
n subsequent USP/NF editions was noted (Table 1). Remark-
ble events during this evolution are the adoption of the paddle
ethod (USP apparatus 2) in 1978, the publication of a gen-
ral chapter on Drug Release in USP 21 (1985), the presence
f 23 monographs for modified-release dosage forms in USP
2-NF 18 (1990), the adoption of the reciprocating cylinder
USP apparatus 3) for extended-release products in 1991 and
he adoption of the flow-through cell in (USP apparatus 4) forSP 22-NF17/1990 462 18 5
SP 23-NF18/1995 501 6 25
SP 24-NF19/2000 552 26 14
SP 29-NF24/2006 619 38 14
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ontrol Services and the Section of Industrial Pharmacists of
he FIP (FIP, 1981).
.2. Research on factors affecting the rate of drug
issolution
During the early stages of drug dissolution research
1950–1960) and in particular after dissolution was established
o be an important factor in the bioavailability of certain drugs,
he detailed study of factors affecting the dissolution rate were
tudied extensively.
The degree of agitation is one of the important factors deter-
ining dissolution. Generally, higher stirring rates result in
igher dissolution rates. This was studied quantitatively as well
nd several publications appeared, that gave experimental evi-
ence of a power law relationship between dissolution rate and
tirring rate (Wurster and Taylor, 1965). Under certain condi-
ions this power-law collapsed to an almost linear relationship.
Dissolution rate depends also directly on solubility, as the
oyes–Whitney equation (Eq. (1)) suggests. This became of
articular importance as the influence of solubility on bioavail-
bility was considered to come primarily from its influence on
issolution rather than saturation of GI fluids. This is so, because
ink conditions were considered to prevail inside the intestines,
t least for highly permeable drugs (Wurster and Polli, 1961;
ibaldi and Feldman, 1967). It was also realized that solubil-
ty can be affected by the presence of solubilizing agents in the
issolution medium either by partitioning of the drug into the
icelles of a surfactant or complexation of the drug with one
r more substances. The seminal articles of Bates et al. (1966)
n griseofulvin dissolution and Tao et al. (1974) on cholesterol
issolution in bile salt solutions can be considered as the ini-
iatory studies on drug dissolution in micellar solutions. Also,
n 1968 the publication of the book “solubilization by surface-
ctive agents and its applications in chemistry and the biological
ciences” marked the new very rapidly growing field (Elworthy
t al., 1968). A method called “solid dispersion formulation”
as also developed in order to enhance the dissolution rate
f sparingly soluble compounds. The drug is dispersed in an
nert hydrophilic carrier, which promotes the dissolution of drug
hrough its high wettability. Dispersion of chloramphenicol in
rea is one of the first classic examples (Chiou, 1971).
Another factor that influences the dissolution rate is the sur-
ace exposed in the solvent. This is primarily affected by the
article size, meaning the smaller the particles, and therefore in
reater number, the higher their total exposed surface compared
o larger but fewer particles of the same total mass. The effect
s especially dramatic with poorly soluble compounds as, for
xample, digoxin which showed 100% increase in bioavailabil-
ty when its particle size was reduced from 100m to approxi-
ately 10m (Jounela et al., 1975). Studies on the effect of par-
icle size were reviewed by Levy (1963). However, the relation-
hip of particle size–surface area–dissolution rate is not always
traightforward. Finholt (1974) clearly demonstrated that if the
rug is hydrophobic and the dissolution medium has poor wet-
ing properties, reduction of particle size may lead to a smaller
ffective surface area and a slower dissolution rate. Finholt
4
eournal of Pharmaceutics 321 (2006) 1–11 5
1974) reported that when granules containing phenacetin in dif-
erent particle sizes were prepared using gelatine as a hydrophilic
iluent their dissolution rate was found to increase as the particle
ize was progressively decreased. On the contrary, when simple
henacetin particles were tested for their dissolution in 0.1N
Cl, the dissolution rate increased as the particle size increased.
he situation was altered returning to normality, when a surface
ctive agent Tween 80 was added to the dissolution medium.
he anomalous behaviour was attributed to the better wetting
f larger particles in comparison to the smaller particles, which
oating on the medium exposed a smaller surface area to the
edium. The addition of surface active agent restored the normal
ituation by improving the wetting of particles. Similar results
ere obtained with phenobarbital and aspirin (Finholt, 1974).
During this period an important contribution to the math-
matical modelling of dissolution curves was published by
angenbucher (1972). He observed that if one plots the quantity
ln(1 −m) versus time on a log–log plot, where m is the accu-
ulated fraction of dissolved material, the curve looks linear,
nd one can then perform linear regression. This is equivalent
o fitting a Weibull equation to the dissolution data:
= 1 − exp
[
−(t − T )b
a
]
(5)
here t is time, T a lag time, a a scale constant and b is a shape
onstant.
. 1980s: Dissolution becomes an essential tool for the
evelopment and evaluation of sustained release
ormulations
The first mention of a constant release oral medication is
uoted in a British patent almost 70 years ago (Lipowski, 1934).
n 1952, Smith Kline and French introduced the first time-
eleased medicine, Dexedrine (dextroamphetamine sulfate). It
as marketed and used in a Spansule—a novel form of drug
elivery (Blythe et al., 1959). Since then the term sustained
elease is in common usage to describe orally administered
roducts that modulate the time course of drug concentration
n the body by releasing the drug over extended time periods.
he selection of a drug candidate for the design of a sustained
elease system depends on various criteria such as short bio-
ogical half-life (t1/2), narrow therapeutic index, efficient GI
bsorption, small daily dose and marketing benefits. Theeuwes
nd Bayne were the first to derive in 1977 a relationship between
1/2, the optimum therapeutic range blood level, Cmax −Cmin,
nd the dosing interval, T, assuming a one-compartment model
ith repetitive intravenous injections at pseudo-steady state
Theeuwes and Bayne, 1977):
≤ 1.44 · t1/2 lnCmax
Cmin
(6).1. Kinetics of drug release
Since late 1970s the development of sustained release deliv-
ry systems evolved rapidly. The basic performance requirement
6 nal J
o
p
t
i
o
r
s
i
d
e
o
a
t
t
p
c
w
t
r
t
i
t
c
i
a
r
b
r
a
m
i
t
b
o
e
p
w
c
a
u
1
f
t
d
c
P
(
s
t
2
h
M
a
t
C
a
(
t
a
i
i
m
e
a
4
f
u
t
1
g
t
t
d
s
c
o
o
t
i
a
p
t
t
a
g
a
q
v
u
d
1
H
f
a
i
pA. Dokoumetzidis, P. Macheras / Internatio
f these systems is that they release drug in vivo according to a
redictable rate. The kinetics of drug release follows the opera-
ive release mechanism of the system, e.g., diffusion through
nert matrix, diffusion across membrane or hydrophilic gel,
smosis, ion-exchange, etc. By far, diffusion is the principal
elease mechanism, since apart from the diffusion-controlled
ystems, diffusion takes place at varying degrees in both chem-
cally and swelling-controlled systems.
Solute release models preceded the development of drug
elivery systems by many years. In fact, the mathematical mod-
lling of drug release from diffusion-controlled systems relies
n the Higuchi model published in 1961 (Higuchi, 1961). He
nalyzed the kinetics of release from an ointment assuming that
he drug is homogeneously dispersed in the planar matrix and
he medium into which it is released acts as a perfect sink under
seudo steady-state conditions. Higuchi derived Eq. (7) for the
umulative amount q(t) of drug released at time t:
q(t)
q∞
= K√t (7)
here q∞ is the cumulative amount of drug released at infinite
ime and K is a composite constant with dimension time−1/2
elated to drug diffusional matrix as well as the design charac-
eristics of the system. Due to the approximate nature of Eq. (7),
ts use for the analysis of release data is recommended only for
he first 60% of the release curve (q(t)/q∞) ≤ 0.60).
In late 1960s, Wang et al. published an article which can be
onsidered as the initiator of the realization that two apparently
ndependent mechanisms of transport, a Fickian diffusion and
case II transport, contribute in most cases to the overall drug
elease (Wang et al., 1969). The former mechanism is governed
y Fick’s law, while the latter reflects the influence of polymer
elaxation on the molecules’ movement in the matrix (Enscore et
l., 1977). Some years later, Fu et al. (1976) used a mechanistic
odel to study the release of a drug homogeneously distributed
n a cylinder. In reality, Fu et al. solved Fick’s second law equa-
ion assuming constant cylindrical geometry and no interaction
etween drug molecules.
In 1985, a date which marks the initial rapid phase of growth
f delivery systems, Peppas (1985) introduced a semi-empirical
quation (the so-called power law) to describe drug release from
olymeric devices in a generalized way:
q(t)
q∞
= K1tn (8)
here K1 is a constant reflecting the structural and geometric
haracteristics of the delivery system expressed in time−n units
nd n is a release exponent the value of which is related to the
nderlying mechanism(s) of drug release (Ritger and Peppas,
987). Again, valid estimates for K1 and n can be derived
rom the fitting of Eq. (8) to the first 60% of the experimen-
al release data. Detailed discussions of the assumptions of the
erivations of Eqs. (7) and (8) in relation to their valid appli-
ations to real data can be found in literature (Siepmann and
eppas, 2001; Macheras and Iliadis, 2006). Since Eqs. (7) and
8) enjoy a wide applicability in the analysis of drug release
tudies, caution should be exercised for their proper use in rela-
a
c
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ion to the elucidation of the release mechanisms (Rinaki et al.,
003b).
Through the years a plethora of mechanistic release models
ave been published in literature (Siepmann and Peppas, 2001;
acheras and Iliadis, 2006). Although the mechanistic models
re more physically realistic, their mathematical complexity is
heir main disadvantage for wide use. In recent years, Monte
arlo simulations following the pioneering work of Bunde et
l. (1985) were used to study drug release from Euclidean
Siepmann et al., 2002, 2004; Kosmidis et al., 2003b) or frac-
al spaces (Kosmidis et al., 2003a). The work of (Kosmidis et
l., 2003a,b) demonstrated that the Weibull function (Eq. (5)),
s the most powerful tool for the description of release kinetics
n either Euclidean or fractal spaces. Based on these findings, a
ethodology was developed (Papadopoulou et al., 2006) for the
lucidation of release mechanisms using the entire set of data
nd the estimate for the exponent b of time.
.2. In vitro in vivo considerations
The major objective in the design of an oral controlled release
ormulation is to achieve little or no effect of the GI environment
pon the rate of drug release. This is a rather difficult goal since
he formulation traverses a varying milieu: from a pH close to
in the fasted stomach through the duodenum (pHs 4–5) and a
radually increasing intestinal pH reaching the alkaline region in
he distal section of the intestinal tract. In parallel, these formula-
ions can be dosed either in presence or absence of food and the
ramatic physiological changes, e.g., pH, bile and pancreatic
ecretions can influence the rate of drug release. Overall, this
omplex-heterogeneous GI environment has a greater impact
n drug dissolution for controlled release formulations than that
bserved with conventional preparations. Based on this realiza-
ion a separate general chapter, Drug Release 〈724〉 was adopted
n the USP 21-NF 16 as early as 1985 providing methodology
nd acceptance criteria for extended-release and delayed-release
roducts (see Table 1).
Dilantin®, an extended-release product of Parke Davis was
he first to have an approved dissolution specification attached
o it as a condition of lot-to-lot approval by the FDA. Shah et
l. (1983) proposed a dissolution window over time to distin-
uish the two types of Dlantin® formulations (100 and 300 mg)
nd ensure lot-to-lot bioequivalence. During the same time, two
uinidine gluconate formulations, Quinaglute Duratabs® (Inno-
ator brand, Berlex) and an unapproved and marketed prod-
ct were found to have quite similar dissolution characteristics
espite of the fact that they were bio-inequivalent (Prasad et al.,
982). The similarity of dissolution profiles was justified in 0.1N
Cl as well as in 0.1N HCl for the first hour and then in pH 7.4
or seven additional hours. Further dissolution studies (Skelly et
l., 1986) in a wide range of pH values (1.0–7.4) revealed signif-
cant differences in the dissolution profiles at the intermediate
H values (2.6–5.8) when the percent (dissolved) was plotted as
function of pH and time in a 3D plot (topographical dissolution
haracterization).
During the early days of 1980s, several reports in litera-
ure (Pedersen, 1981; Lagas and Jonkman, 1983; Pedersen and
A. Dokoumetzidis, P. Macheras / International Journal of Pharmaceutics 321 (2006) 1–11 7
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cig. 5. Theophylline dissolution curves from one of the first studies of drug
aminophylline), (c) Xantair (choline theophyllinate) and (d) Choledyl (cholin
7 ◦C. Reprinted from (Macheras et al., 1987) with permission.
oller-Petersen, 1984; Hendeles et al., 1985) indicated that
ood induced changes in theophylline absorption from a number
f marketed controlled release formulations. These absorption
hanges were associated with formulations exhibiting either pH-
ependent or pH-independent dissolution characteristics while
he fat content of the meal was considered as the major determi-
ant of the so-called “dose dumping”. Since then the term “food
ffect” was coined and its importance is reflected in the specific
equirement for its assessment in the evaluation of bioequiva-
ence of controlled release formulations (FDA, 2002). At that
ime, a variety of in vitro methodologies based on dissolution
ests using media such as oleic acid, sodium deoxycholate and
ilk were developed for predicting “food effect” under in vitro
onditions (Wearley et al., 1985; Maturu et al., 1986; Macheras
t al., 1987, 1989). In Fig. 5, theophylline dissolution curves
rom one of the first studies of drug dissolution in food mim-
cking media (Macheras et al., 1987), are shown. These articles
an be considered as the progenitors of most subsequent work
n bio-relevant dissolution media published a decade later.
. 1980–2000: Emphasis on dissolution as a prognostic
ool of oral drug absorption
Drug absorption is a complex process dependent upon drug
roperties such as solubility and permeability, formulation fac-
ors and physiological variables including regional permeability
ifferences, pH, luminal and mucosal enzymes, and intestinal
otility among others. Despite this complexity, various quali-
ative and quantitative approaches have been proposed for the
stimation of oral drug absorption (Macheras and Iliadis, 2006).
u
t
tution in food mimicking media. (a) Theo-dur (theophylline), (b) Phyllotemp
ophyllinate) tablets, in milk (solid) and phosphate buffer, pH 6.5 (dashed), at
In 1985, Amidon and co-workers, using a pseudoequilibrium
odel, made a major step in the theoretical analysis of oral drug
bsorption when solubility and dose were taken into account for
he estimation of the absorption potential (AP) of a drug, apart
rom the pH-partition hypothesis parameters (lipophilicity, and
egree of ionization) (Dressman et al., 1985). Four years later
quantitative version of the absorption potential concept was
ublished (Macheras and Symillides, 1989) which enabled the
stimation of the fraction of dose absorbed as a function of AP.
owever, the microscopic model based on mass balance consid-
rations and published in 1993 can be considered as a landmark
n the history of oral drug absorption since it revealed the three
undamental parameters, namely, dissolution, absorption and
ose numbers, which control the extent of oral drug absorption
Oh et al., 1993). As a matter of fact, two differential equations,
xpressed in dimensionless variables, were used to describe the
issolution of drug particles and the uptake of the dissolved drug.
his work enabled Amidon et al. (1995) to develop in their sem-
nal paper published in 1995 a Biopharmaceutics Classification
ystem (BCS). According to BCS a substance is classified on
he basis of its aqueous solubility and intestinal permeability,
nd four drug classes were defined i.e., high solubility/high per-
eability (Class I), low solubility/high permeability (Class II),
igh solubility/low permeability (Class III), low solubility/low
ermeability (Class IV). The properties of drug substance were
ombined with the dissolution characteristics of the drug prod-
ct, and predictions with regard to the in vitro–in vivo correla-
ions for each of the drug classes were pointed out.
These advances attracted the obvious interest of scientists in
he importance of dissolution tests as predictors of oral absorp-
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ion for Class II drugs. In an attempt to establish correlations
etween the results of the dissolution tests and the in vivo absorp-
ion data, artificial fluids, simulating gastric and small intestinal
onditions in the fasted state, were developed (Dressman et al.,
998). Also, media mimicking the fed state conditions in the
uman intestinal fluid were proposed (Dressman et al., 1998;
alia et al., 1998; Kostewicz et al., 2002; Persson et al., 2005).
n some cases (Pedersen et al., 2000; Kostewicz et al., 2002;
ersson et al., 2005) the in vitro dissolution rate of poorly sol-
ble drugs in simulated media in the fasted state do not always
orrelate with the dissolution rate in aspirated intestinal fluids.
Although all these studies contribute to the proper selection
f representative media mimicking gastric and small intestinal
onditions, the simulation of the in vivo hydrodynamic con-
itions remains an insuperable obstacle. This is particularly
o since recent studies based on computational fluid dynam-
cs (McCarthy et al., 2003, 2004; D’Arcy et al., 2005) revealed
ot only the complexity of the fluid flow in the everyday use of
asket and paddle methods of dissolution, but also the chaotic
spects of hydrodynamics (D’Arcy et al., 2006). These results
n conjunction with the complexity of (i) gastrointestinal drug
bsorption phenomena (Macheras and Argyrakis, 1997) and (ii)
he heterogeneous in vivo conditions (Weitschies et al., 2005)
ndicate that we are far away from the simulation of the in vivo
ydrodynamics and the proper design of a really prognostic dis-
olution test.
. 2000–present: Dissolution in the framework of BCS
The FDA guidance (FDA, 2000) on BCS issued in 2000
rovides regulatory benefit for highly permeable drugs that are
ormulated in rapidly dissolving solid immediate release formu-
ations. The guidance classifies a substance to be highly soluble
hen the highest dose strength is soluble in 250 mL or less of
queous media over the pH range 1–7.5, while a drug product
s defined as rapidly dissolving when no less than 85% of the
ose dissolves in 30 min using USP Apparatus I at 100 rpm in
volume of 900 mL in 0.1N HCl, as well as in pH 4.5 and
.8 buffers. Thus, petitioners may request biowaivers for high
olubility-high permeability substances (Class I) formulated in
mmediate release dosage forms that exhibit rapid in vitro dis-
olution as specified above.
The reference of the FDA guidance exclusively to “the high-
st dose strength” for the definition of highly soluble drugs
mplies that a drug is always classified in only one class regard-
ess the possible different performance in respect to solubility
f smaller doses used in actual practice. However, this is not
n accord with the dose dependency (non-Michaelian type) of
ral drug absorption, which consistently has been demonstrated
n the early (Dressman et al., 1985; Macheras and Symillides,
989) and recent studies (Boxenbaum, 1999; Sanghvi et al.,
001; Willmann et al., 2003, 2004; Faassen and Vromans, 2004;
inaki et al., 2004). Moreover, the dissolution criteria of the
DA guidance have been characterized as conservative (Kaus
t al., 1999; Yu et al., 2002) and suggestions for broadening
hem have been pointed out (Polli et al., 2004). In a similar
ein, the high solubility definition of the FDA guidance on BCS
t
t
o
cournal of Pharmaceutics 321 (2006) 1–11
as been criticized by Yazdanian et al. (2004) as too strict for
cidic drugs and they also quote “an inherent limitation of the
olubility classification is that it relies on equilibrium solubility
etermination, which is static and does not take into account
he dynamic nature of absorption”. Their remarks were based
n the fact that several non-steroidal anti-inflammatory drugs
xhibit extensive absorption despite their classification in Class
I of the BCS. These experimental observations were explained
y Rinaki et al. (2004) utilizing simulations for the in vivo drug
issolution and wall permeation. However, two recent studies
Kasim et al., 2004; Lindenberg et al., 2004) provide results of
rovisional classification of the drugs contained on the WHO
ssential Drugs List and the top 200 drugs lists from the US,
B, ES, JP and suggest that for more than 60% of oral imme-
iate release drug products on the market today, bioequivalence
ay be regulated based on dissolution testing.
It should be noted that dissolution specifications of the FDA
uidance are not correlated with the drug’s solubility/dose ratio,
hich has been shown to control the rate of drug dissolution
Rinaki et al., 2003a). It was Lansky and Weiss (1999) who
aised a question on this issue for the first time in 1999, and
oon after dose was incorporated explicitly into the fundamental
elationships used routinely in dissolution (Rinaki et al., 2003a;
okoumetzidis et al., 2006). These advances are important for
he quantitative aspects of biopharmaceutics drug classification
Rinaki et al., 2003c) as well as the in vivo dissolution mod-
ling approaches used to interpret the extensive absorption of
lass II drugs (Rinaki et al., 2004). In addition, the extent of
rug dissolution is either directly or indirectly associated to
he solubility/dose ratio assuming the diffusion layer model
Dokoumetzidis et al., 2006). These findings have both theo-
etical and practical interest since they indicate that dissolution
ata contain explicit information regarding the solubility of drug
nd therefore can be in principle used as sole indicators for bio-
harmaeutic drug classification.
. Conclusion
Dissolution research started to develop in 1897 when Noyes
nd Whitney derived their equation in the course of their dissolu-
ion studies on benzoic acid and lead chloride. Thus, dissolution
tarted as a topic in physical chemistry, and is still an impor-
ant subject of research in various sections of physical sciences
Avnir, 1989). The history of the study of dissolution, outlined
ere, makes it clear that the quantitative aspects of the subject
ave been dependent on input from the physical scientists Noyes
nd Whitney, Hixson and Crowell and Levich. Also, the work of
eibull in statistics had a remarkable impact on the quantitative
nalysis of dissolution data.
Alongside that, during the past 35 years, dissolution studies
ave become an essential part of drug applications to regulatory
odies worldwide. In this regard, dissolution tests are used in the
harmaceutical industry for quality control and to assist with
he determination of bioequivalence. Besides, the dissolution
ests provide useful information at several stages of drug devel-
pment. Although scientists wish to establish in vitro–in vivo
orrelations between release of drug from the formulation and
nal J
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rug absorption, the limited knowledge of the complex compo-
ition and hydrodynamics of the gastrointestinal fluids remains a
eal hurdle. The experience gained so far indicates that the design
f a unique dissolution test to be used reliably as a prognostic
ool of oral drug absorption will not appear in the near future.
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